DOW JONES21,917.16-410.32 -1.84%
S&P 5002,584.59-42.06 -1.60%
NASDAQ7,700.10-74.05 -0.95%
 News
Covid-19 activity roundup - healthcare
seekingalpha · 1d ago
Aptorum Group Limited to Present at the Solebury Trout Virtual Investor Conference
Business Wire · 1d ago
Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress
Business Wire · 1d ago
Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT Platform and Acticule Infectious Disease Platform
Business Wire · 1d ago
Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
ACCESSWIRE · 03/24 21:00
OCUL, AIM, INFN and OMI among midday movers
Seeking Alpha - Article · 03/04 17:39
Aptorum Group Announces Closing of $10 Million Registered Direct Offering of Class A Ordinary Shares and Warrants
Business Wire · 02/28 18:00
Mid-Afternoon Market Update: Dow Turns Negative; SmileDirectClub Shares Fall On Downbeat Q4 Results
Benzinga · 02/26 19:53
Mid-Day Market Update: Dow Jumps Over 400 Points; Menlo Therapeutics Shares Plunge
Benzinga · 02/26 17:02
Aptorum Group Prices 1.351M Share, Warrant Offering At $7.40/Share
Benzinga · 02/26 14:30
Aptorum Group Announces Pricing of $10 Million Registered Direct Offering
Business Wire · 02/26 14:15
Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong
Business Wire · 02/24 11:00
Aptorum Group Highlights 'Significant' Progress For SACT-1 For Neuoblastoma Targeting Investigational New Drug Submission In 2H'20
Benzinga · 02/10 13:05
Aptorum Group Highlights Further Data For ALS-4 Small Molecule Anti-Virulence Drug Candidate For Treatment of Infections Caused By Staphylococcus Aureus, On Track Targeted For Investigational New Drug Submission in 2H'20
Benzinga · 02/10 13:02
Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track Targeted For IND Submission in H2 2020
Business Wire · 02/10 13:00
Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020
Business Wire · 02/10 13:00
Did You Manage To Avoid Aptorum Group's (NASDAQ:APM) 13% Share Price Drop?
Simply Wall St. · 01/03 10:38
Aptorum Group Limited Announces Results of 2019 Annual General Meeting
Business Wire · 11/15/2019 13:00
Aptorum Group Limited's (NASDAQ:APM) Single Biggest Risk For Investors
Simply Wall St. · 09/19/2019 13:10
Aptorum Group Limited reports 1H results
seekingalpha · 09/09/2019 15:02